A Phase I First-in-Human, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 232
- 试验地点
- 6
- 主要终点
- Dose escalation:Dose -limiting toxicity (DLT)
研究概览
简要总结
This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary participation and signature of informed consent form;
- •At least 18 years old, male or female;
- •Participants with histologically and/or cytologically confirmed locally advanced/metastatic solid tumors;
- •Participants should have at least one evaluable or measurable tumor lesion;
- •Participants have failed the standard of therapy in the locally advanced/metastatic setting;
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1;
- •Expected survival ≥12 weeks;
- •Adequate organ and bone marrow function;
- •Availability of archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue, or fresh biopsies within 28 days before first administration, is mandatory
排除标准
- •Active second primary malignancies within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence;
- •Symptomatic central nervous system (CNS) metastases or CNS metastases requiring CNS-directed local therapy or corticosteroid treatment that occurred within 2 weeks prior to the first administration of the investigational treatment;
- •Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening;
- •Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study ;
- •Any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment;
- •Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment;
- •Not recovered from previous anticancer therapy-induced AEs(Adverse Events);
- •Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of study treatment;
- •Received prior therapies within the following time frames prior to the first dose of study treatment:
- •Previous cytotoxic therapy, anticancer targeted small molecules within 2 weeks.
- •Anti-cancer antibody, immune checkpoint inhibitor or ADC within 5 half-lives or 4 weeks (whichever is shorter).
- •Chinese medicines/herbal preparations with anticancer indication taken within 2 weeks.
- •Radiation therapy within 4 weeks.
- •Prior exposure to topoisomerase I inhibitor (TOP1i)-based antibody drug conjugate (ADC) therapies or CDH17-targeted ADC therapies.
- •Use of any live vaccine therapy within 4 weeks prior to the first dose of study treatment.
- •Administration of below medications ≤14 days prior to the first dose of study treatment.
- •Strong or moderate CYP3A4 inducers/inhibitors;
- •Drugs with known risk of Torsades de Pointes(TdP);
- •Drugs that may prolong the QT interval;
- •Major surgery within 2 weeks of receiving the first dose of study treatment;
- •Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome ;
- •Active or chronic hepatitis B or hepatitis C infection;
- •Participants with clinically significant cardiovascular diseases;
- •History of allogeneic organ transplantation or graft-versus-host disease;
- •History of hypersensitivity to active or inactive excipients of SIM0609 or drugs with a similar chemical structure or class to SIM0609;
- •Pregnant or nursing (lactating) women;
- •Male participants with female partners of reproductive potential, unless they are using highly effective contraceptive methods from signing of informed consent to 180 days after the last dose of study treatment;
- •Presence of any other condition that may increase the risk associate with study participant or may interfere with the interpretation of study results, and, in the opinion of the Investigator, would make the participant inappropriate for entry into the study.
研究组 & 干预措施
A dose expansion of SIM0609-PDAC cohort
1~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in pancreatic ductal adenocarcinoma (PDAC)
干预措施: dose expansion of SIM0609 in PDAC cohort (Drug)
A dose escalation of SIM0609
Multiple dose levels of SIM0609 will be explored in dose escalation, and determine the maximum tolerated dose.
干预措施: SIM0609 for injection (Drug)
A dose expansion of SIM0609 -CRC cohort
1~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in colorectal carcinoma (CRC)
干预措施: dose expansion of SIM0609 in CRC (Drug)
A dose expansion of SIM0609-GC/GEJC cohort
1~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC)
干预措施: dose expansion of SIM0609 in GC/GEJC cohort (Drug)
A dose expansion of SIM0609-positive other solid tumors cohort
1~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in positive other solid tumors
干预措施: dose expansion of SIM0609 in positive other solid tumors (Drug)
结局指标
主要结局
Dose escalation:Dose -limiting toxicity (DLT)
时间窗: At the end of Cycle 1 (each cycle is 21/28days)
Dose escalation:Safety and Tolerability
时间窗: 2 years
Safety and tolerability: Incidence and severity of AEs and serious adverse events (SAEs) assessed by CTCAE v5.0, changes in laboratory values, vital signs, and ECGs. AE related dose interruptions, dose reduction and treatment discontinuation, dose intensity
Dose escalation: Objective response rate(ORR)
时间窗: 2 years
Proportion of subjects who have a complete or partial response assessed by investigator per RECIST 1.1
次要结局
未报告次要终点